TR201200950T1 - İlerlemiş meme kanseri tedavisi için 500 mg'lik bir dozajda fulvestrant. - Google Patents

İlerlemiş meme kanseri tedavisi için 500 mg'lik bir dozajda fulvestrant.

Info

Publication number
TR201200950T1
TR201200950T1 TR2012/00950T TR201200950T TR201200950T1 TR 201200950 T1 TR201200950 T1 TR 201200950T1 TR 2012/00950 T TR2012/00950 T TR 2012/00950T TR 201200950 T TR201200950 T TR 201200950T TR 201200950 T1 TR201200950 T1 TR 201200950T1
Authority
TR
Turkey
Prior art keywords
fulvestrant
dosage
treatment
breast cancer
advanced breast
Prior art date
Application number
TR2012/00950T
Other languages
English (en)
Turkish (tr)
Inventor
Webster Alan
William Dimery Isaiah
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201200950(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR201200950T1 publication Critical patent/TR201200950T1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2012/00950T 2009-07-27 2010-07-26 İlerlemiş meme kanseri tedavisi için 500 mg'lik bir dozajda fulvestrant. TR201200950T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0912999.0A GB0912999D0 (en) 2009-07-27 2009-07-27 Method-803

Publications (1)

Publication Number Publication Date
TR201200950T1 true TR201200950T1 (tr) 2012-09-21

Family

ID=41066853

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2012/00950T TR201200950T1 (tr) 2009-07-27 2010-07-26 İlerlemiş meme kanseri tedavisi için 500 mg'lik bir dozajda fulvestrant.

Country Status (36)

Country Link
US (1) US20120214778A1 (cg-RX-API-DMAC7.html)
EP (1) EP2459199A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013500324A (cg-RX-API-DMAC7.html)
KR (1) KR20120042843A (cg-RX-API-DMAC7.html)
AT (1) AT510868A2 (cg-RX-API-DMAC7.html)
AU (1) AU2010277373A1 (cg-RX-API-DMAC7.html)
BG (1) BG111123A (cg-RX-API-DMAC7.html)
BR (1) BR112012001837A2 (cg-RX-API-DMAC7.html)
CA (1) CA2768286A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012000226A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ201235A3 (cg-RX-API-DMAC7.html)
DE (1) DE112010003084T5 (cg-RX-API-DMAC7.html)
DK (1) DK201270089A (cg-RX-API-DMAC7.html)
EA (1) EA201200190A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011629A (cg-RX-API-DMAC7.html)
EE (1) EE201200003A (cg-RX-API-DMAC7.html)
ES (1) ES2393323A1 (cg-RX-API-DMAC7.html)
FI (1) FI20125207L (cg-RX-API-DMAC7.html)
GB (2) GB0912999D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20120084A2 (cg-RX-API-DMAC7.html)
HU (1) HUP1200203A3 (cg-RX-API-DMAC7.html)
IL (1) IL217527A0 (cg-RX-API-DMAC7.html)
IS (1) IS8994A (cg-RX-API-DMAC7.html)
LT (1) LT5953B (cg-RX-API-DMAC7.html)
MX (1) MX2012001282A (cg-RX-API-DMAC7.html)
NO (1) NO20120147A1 (cg-RX-API-DMAC7.html)
PE (1) PE20121177A1 (cg-RX-API-DMAC7.html)
PL (1) PL399129A1 (cg-RX-API-DMAC7.html)
RO (1) RO128705A2 (cg-RX-API-DMAC7.html)
RS (1) RS20120022A1 (cg-RX-API-DMAC7.html)
SE (1) SE1250155A1 (cg-RX-API-DMAC7.html)
SG (1) SG177586A1 (cg-RX-API-DMAC7.html)
SK (1) SK500052012A3 (cg-RX-API-DMAC7.html)
TR (1) TR201200950T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011012885A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201406B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
BR112016024332A2 (pt) * 2014-05-21 2017-08-15 Hoffmann La Roche métodos para o tratamento, para a determinação dos compostos a serem utilizados, para a seleção de pacientes, para a monitoração da eficácia terapêutica, para a optimização da eficácia terapêutica, para a identificação de um biomarcador, artigo de fabricação, utilização de gdc-0941, gdc-0941 e um agente de terapia endócrina e composto para a utilização
US20190147986A1 (en) * 2016-05-17 2019-05-16 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
EP3528818B1 (en) * 2016-10-21 2021-09-15 Crescita Therapeutics Inc. Pharmaceutical compositions
US20180153868A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
KR102267378B1 (ko) * 2019-09-10 2021-06-21 가천대학교 산학협력단 C12, c16 또는 c18-세라마이드를 유효성분으로 함유하는 유방암 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
FI20125207A7 (fi) 2012-02-23
FI20125207L (fi) 2012-02-23
PE20121177A1 (es) 2012-09-23
ECSP12011629A (es) 2012-02-29
AT510868A2 (de) 2012-07-15
LT2012006A (lt) 2013-03-25
BR112012001837A2 (pt) 2016-03-15
KR20120042843A (ko) 2012-05-03
CL2012000226A1 (es) 2012-08-31
EP2459199A1 (en) 2012-06-06
CZ201235A3 (cs) 2012-06-27
ZA201201406B (en) 2013-08-28
PL399129A1 (pl) 2012-11-19
CA2768286A1 (en) 2011-02-03
IL217527A0 (en) 2012-02-29
HUP1200203A1 (en) 2012-09-28
RO128705A2 (ro) 2013-08-30
GB2484050A (en) 2012-03-28
ES2393323A1 (es) 2012-12-20
EA201200190A1 (ru) 2012-08-30
NO20120147A1 (no) 2012-04-03
BG111123A (bg) 2012-10-31
MX2012001282A (es) 2012-06-12
AU2010277373A1 (en) 2012-02-09
HUP1200203A3 (en) 2012-12-28
SE1250155A1 (sv) 2012-02-22
US20120214778A1 (en) 2012-08-23
WO2011012885A1 (en) 2011-02-03
DK201270089A (en) 2012-02-24
RS20120022A1 (sr) 2012-10-31
JP2013500324A (ja) 2013-01-07
HRP20120084A2 (hr) 2012-04-30
GB201201486D0 (en) 2012-03-14
SG177586A1 (en) 2012-02-28
EE201200003A (et) 2012-04-16
SK500052012A3 (sk) 2012-04-03
DE112010003084T5 (de) 2012-09-06
GB0912999D0 (en) 2009-09-02
LT5953B (lt) 2013-07-25
WO2011012885A9 (en) 2011-03-24
IS8994A (is) 2012-02-24

Similar Documents

Publication Publication Date Title
ZA201007648B (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
PT2544680E (pt) Uso de inibidores de erbb3 no tratamento de cancro da mama triplo negativo
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
PH12013500543A1 (en) Breast cancer therapeutics
NZ590464A (en) Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
TR201200950T1 (tr) İlerlemiş meme kanseri tedavisi için 500 mg'lik bir dozajda fulvestrant.
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
UY32987A (es) Nuevo uso antitumoral de cabazitaxel
UY33740A (es) Método para tratar el cáncer de mama y cáncer de ovarios
MY162934A (en) Anticancer steroidal lactones unsaturated in position 7 (8)
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
NZ705124A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
TR201900240T4 (tr) Gece idrara çıkışları azaltmak için desmopresin.
HUE031337T2 (hu) Opioidok rezisztens rákos betegek kezelésében történõ alkalmazásra
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
AR073218A1 (es) Anticuerpo antineuropilina 2 humano, induccion de la expresion del gen supresor de tumores p53 por la neutralizacion de la neuropilina 2 para el tratamiento de cancer
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
FR2964323B1 (fr) Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
IN2015KN00676A (cg-RX-API-DMAC7.html)
CL2008001216A1 (es) Compuestos derivados de pirazol-3-il-amino-pirimidina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
AU332909S (en) Hand shower bracket
CL2010001424A1 (es) Compuestos derivados de azacarbolinas; compuestos intermediarios; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento del cancer.
AU322415S (en) Camisole